Kineta Appoints Michael Banks as New Chief Financial Officer

Seattle, WA — (January 2, 2018) Kineta, Inc., a clinical stage biotechnology company focused on the development of novel immunotherapies in oncology, neuroscience and biodefense announced today the appointment of Michael Banks as Chief Financial Officer effective January 8, 2018.  Mr Banks will report to Kineta Chief Executive Officer Shawn Iadonato and will serve on the company’s senior leadership team.

“We are very pleased to welcome aboard a new CFO with Mike’s extensive history of financial management including his experience in initial public offerings,” said Kineta Chief Executive Officer Shawn Iodonato, Ph.D  “Kineta is on a growth path and our financial operations require the experienced leadership that Mike will provide,” Iodonato added.

Prior to joining Kineta, Mr. Banks was the CFO of Trupanion, Inc. where he was in charge of all financial functions and led the company’s initial public offering in 2014.  Befor Trupanion, Mr. Banks was the CFO at Penn Millers Holding Corp where he also led that company’s initial public offering.  Mr. Banks has a depth of experience in strategic planning, financial and treasury operations, investment portfolio management, and public company reporting and compliance.  His background also includes performance management systems, capital raising, enterprise risk management, acquisitions and divestitures, and investor relations.  Mr. Banks graduated from the University of Delaware and started his career working at KPMG.

####

Kineta, Inc. is a clinical stage biotechnology company committed to developing disruptive life science technologies that address unmet patient needs. We have leveraged our expertise in immunology to advance a focused pipeline of investigational drugs in oncology, neuroscience and biodefense. We actively collaborate with a broad array of private, government and industry partners to advance our innovative products. For more information on Kineta visit our website, www.kinetabio.com, follow us on Twitter at @kinetabio, LinkedIn and Like us on facebook.com/KinetaBio.

NOTICE: This document contains certain forward-looking statements, including without limitation statements regarding Kineta’s and Kineta Immuno-Oncology’s plans for pre-clinical and clinical studies, regulatory filings, investor returns and anticipated drug effects in human subjects. You are cautioned that such forward-looking statements are not guarantees of future performance and involve risks and uncertainties inherent in Kineta’s and Kineta Immuno-Oncology’s businesses which could significantly affect expected results, including without limitation progress of drug development, ability to raise capital to fund drug development, clinical testing and regulatory approval, developments in raw material and personnel costs, and legislative, fiscal, and other regulatory measures. All forward-looking statements are qualified in their entirety by this cautionary statement, and neither Kineta nor Kineta Immuno-Oncology undertake any obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.

Contact:
Jacques Bouchy
jbouchy@kineta.us

(206) 378-0400